Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (Nasdaq: TVTX) is a biopharmaceutical company focused on developing and delivering therapies for rare kidney and metabolic diseases. Its commercial portfolio includes FILSPARI (sparsentan), approved in the United States to slow kidney function decline in adults with primary immunoglobulin A… From the company’s description.
In fiscal 2025, Travere Therapeutics, Inc. reported revenue of $490.73M, up 110.5% from fiscal 2024, and a net loss of $50.26M. Its operating margin was −12.8%, and operations generated $37.78M in cash. Over the twelve months to Jun 30, 2026, revenue was $591.33M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Travere Therapeutics, Inc. does
In the company’s own words
Travere Therapeutics, Inc. (Nasdaq: TVTX) is a biopharmaceutical company focused on developing and delivering therapies for rare kidney and metabolic diseases. Its commercial portfolio includes FILSPARI (sparsentan), approved in the United States to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN), and Thiola and Thiola EC (tiopronin), approved to treat cystinuria. FILSPARI is also being evaluated for focal segmental glomerulosclerosis (FSGS), and its application for that use is under FDA review. The company’s late-stage pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU), now in a pivotal Phase 3 study. Travere acquired pegtibatinase through its 2020 acquisition of Orphan Technologies. It commercializes products for people with rare diseases and works with licensing partners to develop and commercialize products in certain markets outside the United States. The company also sold its Chenodal and Cholbam bile-acid product portfolio in 2023.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1438533
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Travere Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Travere Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Travere Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Travere Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Travere Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Travere Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”